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Background: Lobular breast carcinoma usually shows poor responsiveness to chemotherapies and often lacks
targeted therapies. Since FGFR1 expression has been shown to play pivotal roles in primary breast cancer
tumorigenesis, we sought to analyze the status of FGFR1 gene in a metastatic setting of lobular breast carcinoma,
since promising FGFR1 inhibitors has been recently developed.
Methods: Fifteen tissue metastases from lobular breast carcinomas with matched primary infiltrative lobular breast
carcinoma were recruited. Eleven cases showed loco-regional lymph-nodal and four haematogenous metastases.
FGFR-1 gene (8p12) amplification was evaluated by chromogenic in situ hybridization (CISH) analysis. Her-2/neu and
topoisomerase-IIα gene status was assessed. E-cadherin and Hercept Test were also performed. We distinguished
amplification (>6 or cluster of signals) versus gains (3–6 signals) of the locus specific FGFR-1 gene.
Results: Three (20%) primary lobular breast carcinomas showed >6 or cluster of FGFR1 signals (amplification), six
cases (40%) had a mean of three (range 3–6) chromogenic signals (gains) whereas in 6 (40%) was not observed any
abnormality. Three of 15 metastasis (20%) were amplified, 2/15 (13,4%) did not. The ten remaining cases (66,6%)
showed three chromogenic signals.
The three cases with FGFR-1 amplification matched with those primary breast carcinomas showing FGFR-1
amplification. The six cases showing FGFR-1 gains in the primary tumour again showed FGFR-1 gains in the
metastases. Four cases showed gains of FGFR-1 gene signals in the metastases and not in the primary tumours.
Her-2/neu gene amplification was not observed in all cases but one (6%) case. Topoisomerase-IIα was not amplified
in all cases.
Conclusions: 1) a subset of metastatic lobular breast carcinoma harbors FGFR-1 gene amplification or gains of
chromogenic signals; 2) a minor heterogeneity has been observed after matching primary and metastatic
carcinomas; 3) in the era of tailored therapies, patients affected by the lobular subtype of breast carcinoma with
FGFR1 amplification could be approached to the new target biological therapy such as emerging FGFR-1 inhibitors.
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In breast carcinoma, the response to chemotherapy or
targeted therapies varies according to histology [1]. Al-
though effective regimens are currently established for
invasive ductal carcinoma, the treatment efficacy and the
prognosis of other minor types of breast cancer are not
adequately developed. The lobular histotype, the second
most common subtype of breast carcinomas (15%),
actually show poor responsiveness to available che-
motherapies, thus rarely implying tailored therapies
for patients treatments [2,3]. Defining the relationship
between each histological type and the clinicopatholo-
gical response to therapies is essential to optimizing
individualized treatment. Overall, classical lobular breast
carcinoma is orphan of good standard medical therapies
with recognizable high level of efficacy at any clinical end-
points such as overall survival, disease free-survival or
progression free-survival [1,4]. In fact, the Her-2/neu gene
is rarely amplified in lobular carcinoma, avoiding tras-
tuzumab therapeutic chances for most the patients,
and even worse, the topoisomerase-IIa is constantly
not-amplified [2], thus predicting high chances of
chemo-resistance to anthracyclines. In this poor con-
text of medical therapies, new promising predictive
biomarkers, giving chances in selecting appropriate
patients suitable for receiving new effective regimens,
are needed [5,6].
Among several biomarker studied by different tech-
nical approaches, Reis-Filho et al. studied a small series
of primary lobular breast carcinomas and reported six
cases to be with gains of the locus specific FGFR-1 gene,
thus suggesting that receptor FGFR-1 inhibitors may
be useful as therapeutics [7]. Data on the efficacy of
anti-FGFR-1 inhibitor do seem promising [8-10]. The
study reported herein was designed to analyze the
status of FGFR-1 gene in a consecutive series of lobu-
lar breast carcinoma with primary and matched lymph-
nodal and haematogenous metastases from lobular breast
carcinomas, given no data are currently available on the
FGFR-1 gene status in a metastatic setting of lobular
breast carcinomas.
The importance to assess new biomarker in a metastatic
setting is of note because clinical trials are usually designed
with patients affected by an advanced/metastatic disease.
Material and methods
Tissue samples
Fifteen tissue metastases from lobular breast carcinomas
with matched primary infiltrative lobular breast car-
cinoma where recruited from the file of the Department
of Pathology and Diagnostic, University of Verona and
Hospital SacroCuore, Negrar, Verona, Italy. Eleven cases
showed loco-regional lymph-nodal and four haematogen-
ous metastases.We used tissue samples from human participants. All
tissue blocks have been previously declaired to be available
for the purposes of the actual study by the Istitutional
Review Board (study conducted according to the princi-
ples expressed in the Declaration of Helsinki). Our institu-
tional review board and the ethics committee approved
the original human work that produced the tissue sam-
ples. All processing in obtaining the material has been per-
formed after a written informed consent. Full name Ethic/
Institutional Review Board: Nucleo Ricerca&Innovazione,
University of Verona.
Formalin-fixed and paraffin-embedded tumor blocks
were retrieved from archivial file. Whole tissue sections
were cut from each block at 5 μm thickness and were
stained with haematoxylin and eosin. From these sec-
tions one representative of the whole tumor was evalu-
ated. All cases were reviewed: only tumor with complete
lack of ductal structure and with typical lobular features
have been admitted to the study.Immunohistochemical analysis
Estrogen (ER rabbit, SP1, 1:50, Neomarkers) and pro-
gesterone (PgR 636, 1:150, Dako) receptors were evalu-
ated. Ki67% (MM1, 1:50, Novocastra) were also
assessed. Ki67% was considered low when scored <20%,
medium >20 x <50% and high when >50% of neoplastic
nuclei. E-cadherin and GATA-3 immunostaining were
available for each tumor.
According to the recommendations from the manufac-
turer of the HercepTest kit (DAKO, Glostrup, Denmark),
tissue sections mounted on slides and stored at room
temperature were stained within 4 to 6 weeks from sec-
tioning to maintain antigenicity.
HER-2 immunoexpression was assessed by using Hercept
test (Dako) according to datasheet recommandations.Fluorescence in situ hybridization (FISH) analysis
We performed FISH analysis on whole tissue section for
Her-2/neu and topoisomerase-IIα amplification.
FISH was performed by using the PathVysion Her-2/
neu (Abbott/Vysis Inc, Rome) and topoisomerase-IIα
(Dako, Milan) DNA probe kits from. The technical pro-
cedure has been previously described [11]. Two hundred
neoplastic nuclei were counted.
Specimens were determined to be amplified according
to FDA and ASCO/CAP cut-offs values. Polysomy for
chromosome 17 was defined when the ratio was around
1 in tumors having 3 or more locus-specific HER-2/neu
and centromeric 17 signals, similarly for topoisomerase-
IIα gene status.
The slides were examined using an Olympus BX61
(Olympus, Milan) with appropriate filters. The signals
were recorded with a CCD camera (Olympus). Slides were
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Florence).
Chromogenic in situ hybridization analysis (CISH)
FGFR1 gene (8p12) amplification was evaluated by
chromogenic in situ hybridization (CISH) (ZytoLight,
Bremerhaven, Germany) analyses.
CISH was performed in all cases applying the protocol
of the CISH technology of ZytoVysion. This technique
allows advanced specificity and less background due to
the unique ZytoVision Repeat Subtraction Technique and
is characterized by high sensitivity due to enzyme-coupled
polymers for the detection of FGFR-1 gene gains. We fol-
lowed steps of the datasheet ZytoDot-2C protocol.
In normal cells, two distinct dot-shaped signals per nu-
cleus are observed (disomic pattern). We distincted among
cases showing FGFR-1 gains two groups: amplification
if the number of chromogenic signals was >6 per 60
neoplastic nuclei or showing cluster of signals versus sim-
ple gains when the mean score number of chromogenic
signals set in between 3 and 5 per 60 neoplastic nuclei.
Results
In situ results are summarized in Table 1.
Morpho-Immunophenotypical analysis
Morphological appearance and E-cadherin negative
staining confirmed all tumors to be pure lobular infiltra-
tive carcinoma. Thirteen cases out of 15 (86,6%) were
defined as classical, 1 solid (6,6%) and 1 as pleomorphic
lobular carcinoma (6,6%). Four and eleven cases were re-
spectively characterized by haematogenous (1 ovarian, 1
colonic, 1 cerebral and 1 from bone) (Figure 1A, C) and
lymph-nodal (Figure 1B) metastases.
All cases showed positive estrogen and progesterone
immunoexpression (primary tumours and metastases).
Ki67% was low for all cases except for the pleomorphic
type and one classic subtype, which showed respectively
an high and a medium proliferative rate index. Hercept
test scored 0 in 13 cases and 1+ in two cases. GATA-3
was always positive.
Fluorescence in situ hybridization (FISH) analysis
Her-2/neu gene amplification was not observed in all
cases (Figure 1D) but one (6,6%) case in a metastasis.
Topoisomerase-IIα was not amplified in all cases
(Figure 1E).
Chromogenic in situ hybridization (CISH) analysis
Three (20%) primary lobular breast carcinomas showed >6
or cluster of FGFR-1 signals (amplification) (Figure 1F), six
cases (40%) had a mean of three (range 3–6) chromogenic
signals (gains) whereas in 6 (40%) was not observed any
abnormality. Three of 15 metastasis (20%) were amplified,2/15 (13,4%) did not. The ten remaining cases (66,6%)
showed three chromogenic signals.
The three cases with FGFR-1 amplification matched
with those primary breast carcinomas showing FGFR-1
amplification. The six cases showing FGFR-1 gains in
the primary tumour again showed FGFR-1 gains in the
metastases. Four cases showed gains of FGFR-1 gene sig-
nals in the metastases and not in the primary tumours.
Discussion
The data reported herein, show that: 1) FGFR-1 amplifi-
cation is observed in a subset of lymph-nodal and
haematogenous metastases from lobular breast carcin-
oma; 2) minor heterogeneity is scored in matched pri-
mary and metastatic lobular breast carcinomas; 3) in the
era of tailored therapies, patients affected by the lobular
subtype of breast carcinoma with FGFR-1 amplification
may be considered a potential patients’ subset benefiting
from FGFR-1 inhibitor.
The efficacy use of endocrine therapies for hormone
receptor-positive breast cancer and trastuzumab and
lapatinib for targeting HER2-positive tumors has placed
the way for the clinical development of other metastatic
breast cancer targeted therapies [12]. Conversely, the
benefit of anti-VEGF (vascular endothelial growth factor)
monoclonal antibody in the metastatic setting, is still
under investigation, as well as new HER2-targeted agents
and VEGF-targeted agents, dual epidermal growth factor
receptor/HER2-targeted agents, multitargeted tyrosine
kinase inhibitors, and mammalian target of rapamycin and
poly (ADP-ribose) polymerase 1 inhibitors [12]. These
anticancer agents are being tested in clinical trials with
the potential of addressing unmet therapeutic needs in the
metastatic patient population [13].
In the breast cancer scenario, Massabeau et al. evalu-
ated the role of FGFR1 and its ligand, the fibroblast
growth factor 2 in determining the response to chemora-
diotherapy [14]. Among the low/intermediate grade
tumors, FGFR-1 negative tumors did not respond to
chemoradiotherapy, compared with tumors expressing
FGFR-1 among which, almost one half had a good re-
sponse. Among the low and intermediate grade breast
cancers, the FGFR-1 negative tumors were resistant to
chemoradiotherapy. They concluded that the expression
of FGFR-1 in patients’ biopsies may serve as a marker of
response to chemoradiotherapy. Turner et al. concluded
that amplification and overexpression of FGFR1 may be
a major contributor to poor prognosis in luminal-type
breast cancers, driving anchorage-independent prolifera-
tion and endocrine therapy resistance [15]. In our study
we found a subset of lobular breast carcinoma, be char-
acterized by FGFR-1 amplification or gains of chromo-
genic signals, not only in primary tumours but also in the
metastatic tissue. In this context, patients affected by
Table 1 Metastatic lobular breast carcinoma with matched primary tumours: FGFR1 gene status by molecular analysis
FGFR-1 gene status by chromogenic in situ hybridization (CISH) FISH analysis Immunophenotyping
Topoisomerase-IIα Her-2/neu
Primary breast carcinoma Tissue metastases Both primary and metastases HER2 ER PR Ki67%
1 infiltrative lobular breast
carcinoma
amplified lymph-nodal amplified not-amplified not-amplified 0 positive positive high
2 infiltrative lobular breast
carcinoma
amplified lymph-nodal amplified not-amplified not-amplified 0 positive positive low
3 infiltrative lobular breast
carcinoma
amplified haematogenous amplified not-amplified amplified (in
mts)
1+ positive positive low
4 infiltrative lobular breast
carcinoma
gains lymph-nodal gains not-amplified not-amplified 0 positive positive low
5 infiltrative lobular breast
carcinoma
gains lymph-nodal gains not-amplified not-amplified 0 positive positive medium
6 infiltrative lobular breast
carcinoma
gains lymph-nodal gains not-amplified not-amplified 0 positive positive low
7 infiltrative lobular breast
carcinoma
gains lymph-nodal gains not-amplified not-amplified 0 positive positive low
8 infiltrative lobular breast
carcinoma
gains lymph-nodal gains not-amplified not-amplified 0 positive positive low
9 infiltrative lobular breast
carcinoma
gains lymph-nodal gains not-amplified not-amplified 0 positive positive low
10 infiltrative lobular breast
carcinoma
disomic lymph-nodal gains not-amplified not-amplified 0 positive positive low
11 infiltrative lobular breast
carcinoma
disomic lymph-nodal gains not-amplified not-amplified 0 positive positive low
12 infiltrative lobular breast
carcinoma
disomic lymph-nodal gains not-amplified not-amplified 0 positive positive low
13 infiltrative lobular breast
carcinoma
disomic haematogenous gains not-amplified not-amplified 0 positive positive low
14 infiltrative lobular breast
carcinoma
disomic haematogenous disomic not-amplified not-amplified 0 positive positive low
15 infiltrative lobular breast
carcinoma
disomic haematogenous disomic not-amplified not-amplified 0 positive positive low
Amplified: >6 or cluster of signals; gains: 3–5 signals.
ER: estrogen receptor, PR: progesteron receptor.
Brunello et al. Journal of Experimental & Clinical Cancer Research 2012, 31:103 Page 4 of 7
http://www.jeccr.com/content/31/1/103lobular breast carcinomas and characterized by gains/
amplification of FGFR-1 molecule, could receive effective
regimens (predictive biomarker) with FGFR-1 inhibitors
(targeted therapy). Differently, lobular breast carcinomas
usually show absence of Her-2/neu and topoisomerase-IIα
gene amplification (according to both FDA or ASCO/
CAP cut-offs [11]), thus patients constantly lack the ad
hoc predictive rationale for receiving common chemother-
apy that includes anthracyclines; in addition, invasive
lobular carcinomas commonly underexpress Her-2 show-
ing lack of tailored scheme of therapies.
The efficacy of anti-FGFR-1 inhibitor is increasing also
in carcinomas arising from other organs. Interestingly,
Dutt et al. found gains of FGFR-1 gene in a subset of
lung adenocarcinomas and squamous lung carcinomas
and notably they demonstrated that a non-small cell
lung carcinoma cell line harbouring focal amplification
of FGFR-1 is dependent on FGFR-1 activity for cell
growth, as treatment of this cell line either with FGFR1-specific shRNAs or with FGFR small molecule enzymatic
inhibitors did lead to cell growth inhibition [16]. They
concluded that FGFR-1 may represent a promising
therapeutic target in non-small cell lung cancer and even
better in the orphan subtype of lung carcinoma such as
the squamous.
Intratumoral heterogeneity can lead to underestimation
of the tumor genomics portrayed from single tumoral sam-
ples and may present challenges to personalized-medicine
and biomarker development. Intratumor heterogeneity
may foster tumor adaptation and therapeutic failure [17].
We found no significant heterogeneity in matched primary
and metastatic lobular breast carcinomas in regard to
FGFR-1 gains or amplification. The predictive biomarker
may be assessed on metastatic tissue or in primary carcin-
omas, and the predictiveness to anti-FGFR-1 inhibitor is
prone to be similar.
The assessment of the FGFR-1 gene status may be per-
formed on formalin-fixed and paraffin embedded materials,
Figure 1 Metastatic lobular breast carcinoma to the colon (A, H&E), to the lymph-node (B, H&E) and to the bone (C, GATA-3
immunoexpression); FISH analysis showing absence of Her-2/neu (D) and topoisomerase-IIα (E) gene amplification, avoiding selection
of the patients to targeted and individualized chemiotherapies. FGFR-1 gene amplification in a metastasis of lobular breast carcinoma
by CISH analysis (F).
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new clinical trials have to take in account these clustered
molecular patterns in order to make an appropriate cor-
relation between abnormalities of the FGFR-1 gene and
predictiveness of emerging drug efficacy. The clinical
significance in between amplification (>6 chromogenic
signals) versus simple gains (3–6 signals) may be assessed
differently; we actually do not know if anti-FGFR1 inhibi-
tors work equally. Polyploidy of nuclei due to disruption
of the mitotic machinery may be the reasons of simple
gains of cromogenic signals, differently to true gene ampli-
fication where additional gains of signals are more than
reference probes (true gene amplification). We clustered
these two molecular groups similarly to those distinct in
the Her-2/neu assessment when overall gene copy number
is scored.
The FGFR-1 overexpression is already been noted, how-
ever no data is available on its presence in a metastatic
setting. Reis-Filho et al. studied eighteen infiltrative lobular
breast carcinomas and reported gains of FGFR-1 by
arrayCGH in five cases and validated specific gains ofgenomic material after in situ hybridization analysis
[7]. Courjal et al. studied by Southern blotting a total
of 1875 breast tumor DNAs with 26 probes mapping
at 15 distinct chromosomal localizations [18]. They
identified a group of carcinomas with amplifications
at 11q13 and/or 8p12 and was predominantly composed
of estrogen receptor-positive tumors and presented a large
proportion of lobular cancers. Coamplifications of the
11q13 and 8p12 regions are common in breast carcin-
omas, suggesting synergy between the amplicons [19,20].
Gelsi-Boyer et al. found genomic “turbulence” at 8p11
in a subset of lobular breast carcinomas [21] whereas
Adelaide et al. described a recurrent chromosome trans-
location breakpoint near the 8p12 locus [22]. Jacquemier
et al. observed that overexpression of FGFR-1 to be asso-
ciated with small, well-differentiated diploid breast cancers
[23]. Elbauomy Elsheikh et al. suggested that FGFR-1
amplification may be an independent predictor of overall
survival in patients affected by breast carcinoma [24].
The fibroblast growth factor (FGF) signaling axis is
increasingly implicated in tumorigenesis [25] and
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(FGFR) kinase inhibitors are currently in clinical develop-
ment [5,8,26], however, the predominant activity of the
most advanced of these agents is against the kinase insert
domain receptor, which compromises the FGFR selectivity
[27,28]. Most of studies did not encounter the lobular sub-
types of breast carcinoma when evaluating FGFR-1 gene
status. Shiang et al. suggested that FGFR-1 amplification
or protein overexpression in breast cancers may be an in-
dicator for brivanib treatment, where it may have direct
anti-proliferative effects in addition to its’ anti-angiogenic
effects [29]. Gru et al. found a twofold increase in FGFR1
amplification in invasive breast carcinoma versus pure
ductal carcinoma in situ, and they observed a significant
reduction of the disease-free survival in amplified versus
unamplified invasive breast carcinoma [30]. Balko et al.
suggested that the addition of FGFR inhibitors to ER-
targeted therapy will yield a superior antitumor effect [31].
Jang et al. reported the increased frequency of FGFR1
amplification in invasive carcinomas compared with pure
in situ ductal carcinoma [32]. They suggested a role for
FGFR1 amplification in the progression of breast cancer
including in situ-to-invasive transition. Only 3.2% of their
cases had lobular features, thus we can not compare our
findings. Massabeau et al. observed a correlation in be-
tween patients showing response to chemotherapy and
the FGFR-1 positive findings by immunophenotypical ana-
lysis at cancerous tissue level [14]. Moelens et al. reported
around 20-30% of invasive ductal breast carcinoma har-
boring FGFR-1 amplification (ratio >1.3) [33]. Again, no
lobular have been analyses.
Overall, emerging interest is present at any level of
translational research in regard to FGFR-1 as a bio-
marker predictive of responsiveness to targeted and/or
personalized therapies. In the era of tailored therapies,
patients affected by the lobular subtype of breast carcin-
oma with FGFR-1 amplification could be approached to
the new target biological therapy such as FGFR-1 inhibi-
tor, with promising clinical efficacy. The lobular infiltra-
tive breast carcinoma may become an ex orphan cancer
of targeted therapy. In our study, we observed the pres-
ence of FGFR-1 genomic abnormalities such as gains
and amplification in a significant subset of metastatic
lobular breast carcinoma, with clear implications for tar-
geted therapy use.
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